- Home
- ELEV vs XOS Comparison
ELEV vs XOS Comparison
Compare ELEV & XOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- XOS
- Stock Information
- Founded
- ELEV 2019
- XOS 2016
- Country
- ELEV United States
- XOS United States
- Employees
- ELEV N/A
- XOS N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- XOS Construction/Ag Equipment/Trucks
- Sector
- ELEV Health Care
- XOS Consumer Discretionary
- Exchange
- ELEV Nasdaq
- XOS Nasdaq
- Market Cap
- ELEV 22.8M
- XOS 25.6M
- IPO Year
- ELEV 2021
- XOS N/A
- Fundamental
- Price
- ELEV $0.38
- XOS $3.04
- Analyst Decision
- ELEV Hold
- XOS Buy
- Analyst Count
- ELEV 6
- XOS 5
- Target Price
- ELEV $1.77
- XOS $8.80
- AVG Volume (30 Days)
- ELEV 2.0M
- XOS 20.3K
- Earning Date
- ELEV 08-05-2025
- XOS 08-12-2025
- Dividend Yield
- ELEV N/A
- XOS N/A
- EPS Growth
- ELEV N/A
- XOS N/A
- EPS
- ELEV N/A
- XOS N/A
- Revenue
- ELEV N/A
- XOS $48,678,000.00
- Revenue This Year
- ELEV N/A
- XOS $1.45
- Revenue Next Year
- ELEV N/A
- XOS $27.16
- P/E Ratio
- ELEV N/A
- XOS N/A
- Revenue Growth
- ELEV N/A
- XOS N/A
- 52 Week Low
- ELEV $0.22
- XOS $2.73
- 52 Week High
- ELEV $3.28
- XOS $9.15
- Technical
- Relative Strength Index (RSI)
- ELEV 62.35
- XOS 38.59
- Support Level
- ELEV $0.38
- XOS $3.00
- Resistance Level
- ELEV $0.39
- XOS $3.10
- Average True Range (ATR)
- ELEV 0.01
- XOS 0.15
- MACD
- ELEV 0.00
- XOS 0.00
- Stochastic Oscillator
- ELEV 85.00
- XOS 6.67
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.